

해외 바이오의약품 임상 현황 (2019.10.01~2019.10.07)

한국바이오의약품협회, 2019.10.8
출처: ClinicalTrials.gov

○ 미국 66건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04108481	Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer	Colorectal Cancer Metastatic Colon Cancer Metastatic Colorectal Cancer Rectal Cancer Liver Metastasis Colon Cancer Colo-rectal Cancer Colorectal Adenocarcinoma Colorectal Neoplasms Liver Metastases Colorectal Carcinoma	Drug: Durvalumab Radiation: Yttrium-90 RadioEmbolization	University of Iowa Biocompatibles UK Ltd AstraZeneca	Phase 1 Phase 2
NCT04080245	Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)	Influenza, Human	Biological: Treatment Group Live Attenuated Flu Vaccine (LAIV)	University of Alabama at Birmingham	Phase 1 Phase 2
NCT04046900	Modifying Organisms Transvaginally in Females	Recurrent Bacterial Vaginosis	Biological: Vaginal microbiome transplant Drug: Oral Metronidazole Other: Sterile saline	Douglas Kwon Massachusetts General Hospital	Phase 1 Phase 2
NCT04046107	Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy	Hepatitis B Virus	Biological: Cemiplimab	National Institute of Allergy and Infectious Diseases (NIAID) Regeneron Pharmaceuticals	Phase 1 Phase 2
NCT04035109	Anakinra as a Rescue Treatment for Allergic Inflammation	Asthma, Allergic	Drug: Anakinra Drug: Preservative-free 0.9% sodium chloride (Placebo) Biological: House dust mite allergen Biological: Cat hair allergen	University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI)	Phase 1 Phase 2
NCT03981549	Treatment of Central Retinal Vein Occlusion Using Stem Cells Study	Central Retinal Vein Occlusion	Biological: Autologous Bone Marrow CD34+ Stem Cells Biological: Sham Therapy	The Emmes Company, LLC National Eye Institute (NEI) University of California, Davis	Phase 1 Phase 2
NCT03973879	Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma	Malignant Glioma	Biological: PVSRIPO Drug: Atezolizumab	Darell D. Bigner, MD, PhD Istari Oncology, Inc. Genentech, Inc. Duke University	Phase 1 Phase 2
NCT03971487	Ocrelizumab for Psychosis by Autoimmunity	Schizo-Affective Type of Psychosis Schizophrenia	Behavioral: Psychosis and cognitive assessments Behavioral: Physical and neuro-cognitive evaluations Diagnostic Test: Safety labs and electrocardiogram Biological: Ocrelizumab infusion	The Methodist Hospital System Genentech, Inc.	Phase 1 Phase 2
NCT03922139	Botox for the Treatment of Chronic Exertional Compartment Syndrome	Compartment Syndrome of Leg	Drug: OnabotulinumtoxinA Injection	University of Wisconsin, Madison	Phase 1 Phase 2
NCT04116775	Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.	Prostate Cancer Prostate Cancer Metastatic	Biological: Fecal microbiota transplant Drug: Pembrolizumab Drug: Enzalutamide	Julie Graff, MD Merck Sharp & Dohme Corp. Prostate Cancer Foundation Johns Hopkins University Oregon Health and Science University Portland VA Medical Center	Phase 2
NCT04113018	Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma	Multiple Myeloma	Drug: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab	Saad Z. Usmani, MD Amgen Celgene Janssen, LP Atrium Health	Phase 2
NCT04106362	Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma	Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 KRAS Protein Variant Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Biological: Cetuximab Drug: Cisplatin Other: Quality-of-Life Assessment Other: Questionnaire Administration Radiation: Radiation Therapy	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	HLA-A2 Positive Cells Present Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintalolimid	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04091737	CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease	Anemia, Sickle Cell	Biological: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human ̑-globinG16D and short-hairpin RNA734	CSL Behring	Phase 1
NCT04074746	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	Recurrent Anaplastic Large Cell Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Classic Hodgkin Lymphoma Recurrent Mycosis Fungoides Recurrent Peripheral T-Cell Lymphoma Refractory Anaplastic Large Cell Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Classic Hodgkin Lymphoma Refractory Mycosis Fungoides Refractory Peripheral T-Cell Lymphoma TNFRSF8 Positive	Biological: Anti-CD30/CD16A Monoclonal Antibody AFM13 Drug: Cyclophosphamide Drug: Fludarabine Drug: Fludarabine Phosphate Biological: Genetically Engineered Lymphocyte Therapy	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04073160	TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer	Bladder Cancer	Drug: Tremelimumab Drug: Durvalumab Radiation: Bladder radiation Drug: Intravesicular Therapy	Daniel George, MD AstraZeneca Duke University	Phase 1
NCT04070781	Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease	Steroid Refractory GVHD Graft Vs Host Disease	Drug: Itacitinib Drug: Tocilizumab	Columbia University Incyte Corporation	Phase 1
NCT04070768	Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia Big Ten Cancer Research Consortium BTCRC-AML17-113	Acute Myeloid Leukemia	Drug: Gemtuzumab Ozogamicin Drug: Venetoclax	Big Ten Cancer Research Consortium Pfizer AbbVie	Phase 1
NCT04061746	Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells	Diabetes Mellitus, Type 1	Biological: Mesenchymal Stem Cells (MSCs) Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)	Medical University of South Carolina National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1

해외 바이오의약품 임상 현황 (2019.10.01~2019.10.07)

한국바이오의약품협회, 2019.10.8
출처: ClinicalTrials.gov

NCT04049383	CAR-20/19-T Cells in Pediatric Patients With Relapsed/Refractory B Cell ALL	Acute Lymphoblastic Leukemia, in Relapse Acute Lymphoblastic Leukemia With Failed Remission Acute Lymphoblastic Leukemia Recurrent Acute Lymphoblastic Leukemia Not Having Achieved Remission Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia	Biological: CAR-20/19-T cells	Medical College of Wisconsin Children's Hospital and Health System Foundation, Wisconsin	Phase 1
NCT04047979	Systems Biology of Zoster Vaccine	Zoster Zoster Varicella Shingles Chicken Pox	Biological: Shingrix	Emory University National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
NCT04044534	Intranasal Insulin for Posttraumatic Stress Disorder	PTSD	Drug: Intranasal insulin Drug: Placebo	VA Connecticut Healthcare System	Phase 2
NCT04028700	The Impact of Oxidative Stress on Erythrocyte Biology	Sickle Cell Disease Without Crisis	Biological: Red Blood Cell Transfusion	Blood Center of Wisconsin Columbia University Medical College of Wisconsin	Phase 2
NCT04025580	Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine	Healthy Volunteer	Biological: Flucelvax Biological: Fluvirin Biological: Fluzone High Dose	National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health Clinical Center (CC)	Phase 2
NCT04025216	A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers	Non-Small Cell Lung Cancer Ovarian Cancer Fallopian Tube Cancer Triple Negative Breast Cancer Multiple Myeloma Pancreatic Ductal Adenocarcinoma	Biological: CART-TnMUC1 Drug: Cyclophosphamide Drug: Fludarabine	Tmunity Therapeutics	Phase 1
NCT04023071	FT516 in Subjects With Advanced Hematologic Malignancies	Acute Myelogenous Leukemia B-cell Lymphoma	Drug: FT516 Drug: Rituximab Drug: Obinutuzumab Drug: Cyclophosphamide Drug: Fludarabine Drug: IL-2	Fate Therapeutics	Phase 1
NCT04019964	Nivolumab in Biochemically Recurrent dMMR Prostate Cancer	Prostate Cancer Recurrent Prostate Cancer	Drug: Nivolumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 2
NCT04015336	E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer	Papillomavirus Infections Oropharyngeal Neoplasms	Biological: E7 TCR	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2
NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	CD19 Positive CD20 Positive Recurrent Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Mantle Cell Lymphoma Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Small Lymphocytic Lymphoma	Biological: Chimeric Antigen Receptor T-Cell Therapy Drug: Cyclophosphamide Drug: Fludarabine Phosphate Biological: Tocilizumab	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) Parker Institute for Cancer Immunotherapy	Phase 1
NCT04003649	IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma	Recurrent Glioblastoma Refractory Glioblastoma	Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR Truncated CD19-expressing Autologous TN/MEM Cells Biological: Ipilimumab Biological: Nivolumab Other: Quality-of-Life Assessment Other: Questionnaire Administration	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03995901	A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation	Transplanted Organ Rejection	Biological: FCR001	Talaris Therapeutics Inc.	Phase 3
NCT03993327	An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer	Colorectal Carcinoma Metastatic in the Liver Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Iodine I 124 Monoclonal Antibody M5A Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03991884	Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia	Blasts 5 Percent or More of Bone Marrow Nucleated Cells Blasts 5 Percent or More of Peripheral Blood White Cells CD22 Positive Recurrent B Acute Lymphoblastic Leukemia Recurrent B Lymphoblastic Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory B Lymphoblastic Lymphoma	Drug: Etoposide Drug: Doxorubicin Drug: Doxorubicin Hydrochloride Drug: Vincristine Drug: Vincristine Sulfate Drug: Prednisone Drug: Cyclophosphamide Biological: Inotuzumab Ozogamicin Biological: Rituximab	University of Washington National Cancer Institute (NCI)	Phase 1
NCT03969446	Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory	Acute Myeloid Leukemia High Risk Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent High Risk Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory High Risk Myelodysplastic Syndrome Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia	Drug: Decitabine Biological: Pembrolizumab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03960541	CD24Fc Administration to Decrease LDL and Inflammation in HIV Patients (CALIBER)	HIV Infections Dyslipidemias	Drug: CD24Fc (human CD24 extracellular domain and human IgG1 Fc fusion protein) Drug: Saline Solution	Oncolimmune, Inc. University of Maryland, Baltimore	Phase 2
NCT03943537	Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders	Psychosis Schizophrenia Schizoaffective Disorder Bipolar I Disorder	Drug: Intranasal Insulin	McLean Hospital	Phase 2
NCT03939585	Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT	Allogeneic Stem Cell Transplant Candidate Acute Myeloid/Lymphoblastic Leukemia Myelodysplastic Syndrome Myeloproliferative Neoplasm Lymphoproliferative Disorders	Biological: Cellular therapy product	Case Comprehensive Cancer Center	Phase 1
NCT03932409	Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer	Endometrial Cancer	Drug: Pembrolizumab Radiation: Radiation Therapy	University of Oklahoma Merck Sharp & Dohme Corp.	Phase 1
NCT03925532	Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant	Allogeneic Hematopoietic Stem Cell Transplantation Recipient Osteopenia Osteoporosis	Biological: Denosumab	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT03889782	High Dose IL-2 in Combination With Anti-PD-1 in Metastatic Melanoma and Renal Cell Carcinoma	Metastatic Melanoma Renal Cell Carcinoma	Drug: Nivolumab Drug: IL2	Mina Nikanjam University of California, San Diego	Phase 2

해외 바이오의약품 임상 현황 (2019.10.01~2019.10.07)

한국바이오의약품협회, 2019.10.8
출처: ClinicalTrials.gov

NCT03865706	Inulin for Infections in the Intensive Care Unit	Antibiotic Resistant Infection Nosocomial Infection Pathogen Transmission Nutrition Disorders Critical Illness Sepsis	Drug: Inulin Oral Suspension Drug: Placebo Oral Suspension Drug: Broad-spectrum antibiotics	Columbia University	Phase 2
NCT03865082	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)	Solid Tumor	Drug: Tilsotolimod Drug: Nivolumab Drug: Ipilimumab	Idera Pharmaceuticals, Inc. Bristol-Myers Squibb	Phase 2
NCT03680508	TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer	Adult Primary Liver Cancer Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer	Drug: TSR-022 and TSR-042	University of Hawaii Tesar, Inc.	Phase 2
NCT03679624	Daratumumab Plus Ibrutinib in Patients With Waldenström's Macroglobulinemia	Waldenstrom Macroglobulinemia Waldenstrom's Disease Waldenström; Hypergammaglobulinemia Waldenstrom's Macroglobulinemia Recurrent Waldenstrom's Macroglobulinemia of Lymph Nodes Waldenstrom's Macroglobulinaemia, Without Mention of Remission Waldenstrom's Macroglobulinemia Refractory	Drug: Ibrutinib Drug: Daratumumab	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC Mayo Clinic	Phase 2
NCT03618381	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	Pediatric Solid Tumor Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcoma Synovial Sarcoma Clear Cell Sarcoma Malignant Peripheral Nerve Sheath Tumors Desmoplastic Small Round Cell Tumor Soft Tissue Sarcoma Neuroblastoma	Biological: second generation 4-1BB EGFR806-EGFRt Biological: second generation 4-1BB EGFR806-EGFRt and a second generation 4 1BB CD19-Her2tG	Seattle Children's Hospital	Phase 1
NCT03617445	Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients	Clostridium Difficile Infection Recurrence	Drug: FMT enema Drug: Oral Vancomycin Drug: FMT enema placebo Drug: Oral Vancomycin placebo	University of Wisconsin, Madison	Phase 2
NCT03056378	POOLED Red Blood Cells Prepared From Pooling 5 Leukoreduced, Irradiated RBC Units	Transfusion Reaction Anemia	Biological: Standard RBCs	New York Blood Center Westchester Medical Center	Phase 1
NCT04090528	pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer	Castration-resistant Prostate Cancer Metastatic Cancer Prostate Cancer	Biological: pTVG-HP Biological: pTVG-AR Drug: Pembrolizumab Drug: rhGM-CSF	University of Wisconsin, Madison Merck Sharp & Dohme Corp. Madison Vaccines, Inc Prostate Cancer Foundation	Phase 2
NCT04042506	SBRT as a Vaccination for Metastatic Melanoma	Metastatic Melanoma	Drug: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] Radiation: Stereotactic Body Radiation Therapy (SBRT)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 2
NCT03920878	Cataract DME - Peri vs. Intraop	Diabetic Macular Edema Cataract	Drug: Aflibercept injected Pre- and Post-operatively Drug: Aflibercept injected intraoperatively	Emory University	Phase 2
NCT03834688	Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age	Mantle Cell Lymphoma	Drug: Venetoclax Drug: Bendamustine Drug: Rituximab	PrECOG, LLC Genentech, Inc.	Phase 2
NCT03529422	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCN	Larynx Lip Oral Cancer Digestive Organs--Diseases	Drug: Durvalumab Radiation: Intensity Modulated Radiotherapy Treatments Drug: Tremelimumab	UNC Lineberger Comprehensive Cancer Center AstraZeneca	Phase 1
NCT03918252	Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma	Mesothelioma	Drug: Nivolumab Injection Drug: Ipilimumab Injection	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 2 Phase 3
NCT04098250	Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH	Post-Traumatic Headache	Drug: Erenumab Other: Placebo	Mayo Clinic University of Arizona Translational Genomics Research Institute Arizona State University Phoenix VA Health Care System United States Department of Defense Amgen	Phase 2
NCT04009668	Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	FSGS MCD Focal Segmental Glomerulosclerosis Minimal Change Disease	Drug: adalimumab	University of Michigan New York University	Phase 2
NCT03960554	The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients	Osteoporosis Renal Osteodystrophy Kidney Transplant; Complications	Drug: Denosumab Inj 60 mg/ml Other: Placebo	Thomas Nickolas, MD MS Columbia University	Phase 2
NCT04088734	Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease	MPS IIIA Sanfilippo Syndrome Sanfilippo A Mucopolysaccharidosis III	Drug: ABO-102	Abeona Therapeutics, Inc	Phase 1 Phase 2
NCT04066114	Treg Modulation With CD28 and IL-6 Receptor Antagonists	Living-Donor Kidney Transplant Kidney Transplant Recipients	Biological: lulizumab pegol Biological: antithymocyte globulin (rabbit) Drug: methylprednisolone Biological: tocilizumab Drug: Prednisone Drug: everolimus Biological: belatacept Drug: mycophenolate mofetil Drug: mycophenolic acid	National Institute of Allergy and Infectious Diseases (NIAID) Bristol-Myers Squibb Clinical Trials in Organ Transplantation	Phase 1 Phase 2
NCT04099277	A Study of LY3435151 in Participants With Solid Tumors	Solid Tumor Triple-negative Breast Cancer Gastric Adenocarcinoma Head and Neck Squamous Cell Carcinoma Cervical Carcinoma High Grade Serous Ovarian Carcinoma Hepatocellular Carcinoma Undifferentiated Pleomorphic Sarcoma Leiomyosarcoma	Drug: LY3435151 Drug: Pembrolizumab	Eli Lilly and Company	Phase 1
NCT04096950	Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury	Spinal Cord Injury	Biological: MT-3921 Low dose Biological: MT-3921 High dose	Mitsubishi Tanabe Pharma Development America, Inc.	Phase 1
NCT04071158	A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS	Respiratory Tract Infection	Biological: RSV Vaccine Biological: Tdap Biological: Placebo	Pfizer	Phase 2
NCT04066348	TNF-α Treatment of Blast-Induced Tinnitus	Blast-Induced Tinnitus, Noise Induced Tinnitus	Biological: Etanercept	Wayne State University Brooke Army Medical Center Portland VA Medical Center John D. Dingell VA Medical Center University of Arizona University of Iowa University of Miami University of Illinois at Urbana-Champaign	Phase 2

해외 바이오의약품 임상 현황 (2019.10.01~2019.10.07)

한국바이오의약품협회, 2019.10.8
출처: ClinicalTrials.gov

NCT04049760	Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease	Fabry Disease	Drug: migalastat HCl 150 mg	Amicus Therapeutics	Phase 3
NCT03744910	Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) Decline	Antibody-mediated Rejection	Biological: Clazakizumab Drug: Normal saline	Vitaeris INC ICON Clinical Research	Phase 3
NCT03847909	A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2	Primary Hyperoxaluria Type 1 (PH1) Primary Hyperoxaluria Type 2 (PH2) Kidney Diseases Urologic Diseases Genetic Disease	Drug: DCR-PHXC Drug: Sterile Normal Saline (0.9% NaCl)	Dicerna Pharmaceuticals, Inc.	Phase 2
NCT03958877	A Study to Evaluate the Safety, Tolerability, and Efficacy of BII017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: BII017 (peginterferon beta-1a) Drug: Interferon beta type 1a	Biogen	Phase 3
NCT04095273	Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug	Advanced Solid Tumors	Drug: BAY1895344 Drug: Pembrolizumab	Bayer	Phase 1
NCT03915184	Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma	Multiple Myeloma	Biological: CT053	Carsgen Therapeutics, Ltd.	Phase 1
NCT03996486	Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia	Hemophilia	Drug: BAY1093884	Bayer	Phase 1

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04102007	A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab	Plaque Psoriasis	Drug: Risankizumab	AbbVie	Phase 3

○ 프랑스 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04113226	Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma	Chemotherapy Diffuse Large B-Cell Lymphoma (DLBCL), Nos Elderly	Drug: Rituximab Drug: Lenalidomide 20 MG Other: Comprehensive Geriatric Assessment (CGA) Other: Activities of daily living (ADL) scale	Centre Hospitalier Universitaire, Amiens cimiez hospital Nice Institut Bergonié groupe hospitalier public sud de l'oise Henri Mondor University Hospital Centre Henri Becquerel Hôpital Charles Foix Saint-Louis Hospital, Paris, France	Phase 2
NCT03892785	Methotrexate Versus Tocilizumab for Treatment of Giant Cell Arteritis: a Multicenter, Randomized, Controlled Trial	Giant Cell Arteritis	Drug: Prednisone treatment Drug: Tocilizumab treatment Drug: Methotrexate treatment Other: Questionnaires Biological: Blood samples	Centre Hospitalier Universitaire Dijon	Phase 3
NCT03274375	Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis	Anti-NMDAR Encephalitis	Drug: IA session Drug: Rituximab	Assistance Publique - Hôpitaux de Paris	Phase 2
NCT03088293	Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)	Idiopathic Refractory Scleritis	Drug: Infliximab Drug: Cyclophosphamide	Hospices Civils de Lyon	Phase 3
NCT03968198	Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia	Critical Limb Ischemia and Peripheral Artery Disease	Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell)	University Hospital, Toulouse Institut National de la Santé Et de la Recherche Médicale, France Etablissement Français du Sang	Phase 2
NCT04108026	Immunotherapy in Patient With Poor General Condition	Non-small Cell Lung Cancer Stage IV	Drug: Durvalumab	Intergroupe Francophone de Cancerologie Thoracique	Phase 2
NCT04102007	A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab	Plaque Psoriasis	Drug: Risankizumab	AbbVie	Phase 3
NCT03744910	Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) Decline	Antibody-mediated Rejection	Biological: Clazakizumab Drug: Normal saline	Vitaeris INC ICON Clinical Research	Phase 3

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04109508	A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets	Healthy Volunteers Type 2 Diabetes	Drug: Oral semaglutide	Novo Nordisk A/S	Phase 1
NCT04102007	A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab	Plaque Psoriasis	Drug: Risankizumab	AbbVie	Phase 3

해외 바이오의약품 임상 현황 (2019.10.01~2019.10.07)

한국바이오의약품협회, 2019.10.8
출처: ClinicalTrials.gov

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04067518	A Clinical Study of SHP674 in Patients With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia	Acute Lymphoblastic Leukemia	Biological: Pegaspargase	Institut de Recherches Internationales Servier Kyowa Kirin Co., Ltd. ADIR, a Servier Group company Servier	Phase 2
NCT03905525	Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome	Sjögren Syndrome	Drug: CFZ533 Other: Placebo	Novartis Pharmaceuticals Novartis	Phase 2
NCT04099277	A Study of LY3435151 in Participants With Solid Tumors	Solid Tumor Triple-negative Breast Cancer Gastric Adenocarcinoma Head and Neck Squamous Cell Carcinoma Cervical Carcinoma High Grade Serous Ovarian Carcinoma Hepatocellular Carcinoma Undifferentiated Pleomorphic Sarcoma Leiomyosarcoma	Drug: LY3435151 Drug: Pembrolizumab	Eli Lilly and Company	Phase 1

○ 중국 9건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03863002	Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure	Liver Failure, Acute on Chronic	Biological: Mesenchymal Stem Cell	Tianjin Weikai Bioeng., Ltd. Tianjin Nankai Hospital	Phase 1 Phase 2
NCT04101760	Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer	Chemotherapy-induced Neutropenia Febrile Neutropenia, Drug-Induced Epithelial Ovarian Cancer Colony Stimulating Factors Adverse Reaction Granulocyte Colony Stimulating Factor Cost-effectiveness Analysis Quality of Life Progression-free Survival Overall Survival	Drug: Long-acting granulocyte colony stimulating factor Drug: Short-acting granulocyte colony stimulating factor	Lei Li Beijing Hospital China-Japan Friendship Hospital The Sixth Medical Center of PLA General Hospital the Seventh Medical Center of PLA General Hospital Peking Union Medical College Hospital	Phase 3
NCT04099589	Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma	Upper Tract Urinary Carcinoma Muscle Invasive Bladder Cancer	Drug: Toripalimab	Jianzhong Shou Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
NCT04098770	Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients	AIDS Patients	Biological: Allogeneic Adoptive Immune Therapy	Beijing 302 Hospital	Phase 2
NCT04047186	Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules	Multiple Pulmonary Nodules	Drug: Nivolumab Injection	Tongji Hospital	Phase 2
NCT03917966	Single-arm, Open-label, Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma	Locally Advanced Esophageal Squamous Cell Carcinoma	Drug: SHR-1210+Paclitaxel+nedaplatin	The First Affiliated Hospital of Zhengzhou University Jiangsu HengRui Medicine Co., Ltd.	Phase 2
NCT03898895	Combination of Radiotherapy With Anti-PD-1 Antibody for unresectable Intrahepatic Cholangiocarcinoma	Intrahepatic Cholangiocarcinoma Radiotherapy Immunotherapy	Combination Product: Radiotherapy+anti-PD-1 Drug: Gemcitabine+cisplatin	Sun Yat-sen University	Phase 2
NCT03817658	A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC	Esophageal Squamous Cell Carcinoma	Drug: SHR-1210 Drug: Placebo	The First Affiliated Hospital of Zhengzhou University Jiangsu HengRui Medicine Co., Ltd.	Phase 2
NCT04109547	A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes	Diabetes Mellitus, Type 2	Drug: Oral semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3